3European Association for the Study of the Liver Clinical Practice Guidelines Panel.EASL Clinical Practice Guidelines:management of chronic hepatitis B[J].J Hepato1,2009,50:227-242.
4Liaw YF,Leung N,Kao JH,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2008 update[J].Hepatol Int,2008,2:263-283.
5Janssen HL,van Zonneveld M,Senturk H,et al.Pegylated interferon alfa-26 alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:a randomised trial[J].Lancet,2005,365:123-129.
6McHutchison JG,Lawitz EJ,Shiffman ML,et al.Peginterferon Alfa2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection[J].N Engl J Med,2009,361:580-593.
7Lok AS,Lai CL,Leung N,et al.Long-term safety of lamivudine treatment in patients with chronic hepatitis B[J].Gastroenterology,2003,125:1714-1722.
8Marcellin P,Chang TT,Lim SG,et al.Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J].Hepatology,2008,48:750-758.
9Hadziyannis S,Tassopoulos N,Heathcote E,et al.Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years[J].Gastroenterology,2006,131:1743-1751.
10Tenney DJ,Rose RE BC,Pokornowski KA,et al.Long-term monitoring shows hepatitis B virus resistance in nucleoside-naive patients is rare through 5 years of therapy.Hepatology,2009,49:1503-1514.
二级参考文献15
1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
7Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9):643-646. 被引量：830
1van Nunen AB,Janssen HL,Wolters LM,et al.Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug?[J].Antiviral Res,2001,52(2):139-146.
